What Immune Insight does

Immune Insight is a France-based Contract Research Organization founded in 2016 as a spin-off from academic research at the Institut Pasteur de Lille. It specializes in ex-vivo and in-vivo assessment of compounds on the immune system, with a particular focus on regulatory T cells (Tregs), serving pharmaceutical and biotechnology clients developing therapeutics in oncology, autoimmunity, and inflammatory diseases. The company's portfolio centers on three service pillars: a proprietary TregSign Kit based on an 80-gene molecular signature that delivers single-assay transcriptomic profiling across eight Treg functional clusters; a cellular insight suite covering PBMC/Treg suppression assays, immunomonitoring, immunophenotyping, and secretion, viability, and tumor infiltration analyses; and animal insight services using syngeneic and PDX-Like humanized cancer models in SCID mice for preclinical efficacy and toxicity studies.

The business operates on a professional-services CRO model with quote-based, project-specific pricing and a direct B2B sales motion that begins with needs discovery, proceeds through custom experimental design, and ends with comprehensive technical reporting and data review sessions. Immune Insight monetizes its privileged access to the Pasteur and CNRS technological ecosystem (animal housing, imaging platforms, shared facilities) and the deep domain expertise of its scientific founders, who hold more than 20 years of onco-immunology and Treg biology experience. The company is privately held, headquartered at the Institut de Biologie de Lille on the Institut Pasteur de Lille campus, and reports a headcount of 1-10 employees.

Name

Immune Insight

Legal name

Immune Insight

Website

https://immune-insight.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Contract Research Organization / Preclinical Immunology Services

NAICS

Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

akta.pro secondary industries

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)

Keywords

• Contract research organization
• Regulatory T cells
• Preclinical immunology services
• Immuno-oncology research
• Humanized cancer models

Headquarters

HQ city

Lille

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Contract Research Services: CRO providing specialized research services to pharmaceutical and biotech companies for drug discovery and development. Services include ex-vivo and in-vivo assessment of compounds on the immune system and regulatory T cells. Revenue generated through custom-designed experimental protocols and comprehensive technical/scientific reports delivered to clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Immune Insight is a contract research organization (CRO) that delivers ex-vivo and in-vivo preclinical assessment of compounds on the immune system, with a specialist focus on regulatory T cells (Tregs). Service offerings include molecular transcriptomic profiling via the proprietary TregSign Kit, cellular immunomonitoring/immunophenotyping assays, and custom humanized in vivo cancer models for efficacy and safety studies, supplied to pharmaceutical and biotech drug discovery programs.

Product overview

Immune Insight is a Contract Research Organization (CRO) specializing in ex-vivo and in-vivo assessment of compounds on the immune system, specifically regulatory T cells (Tregs). The company's portfolio includes the TregSign Kit for molecular transcriptomic analysis, immunomonitoring services (PBMC/Treg Suppression Assay, immunophenotyping), and pre-clinical in vivo cancer models (PDX-Like models). These offerings support drug discovery and development through lead identification, safety assessment, immunotoxicity evaluation, and patient stratification in the fields of cancer, autoimmunity, and inflammatory diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• TregSign Kit A molecular signature tool based on expression of 80 genes related to natural Tregs, induced Tregs, and their microenvironment, enabling complete transcriptomic study of regulatory T cells in a single assay. It establishes 8 gene clusters — Phenotype, Suppressive function, Expansion, Induction, Adhesion, Activation state, Migration, Infiltration, and Plasticity — and determines the impact of a candidate molecule on Tregs and their microenvironment. Targeted at pharmaceutical and biotech drug discovery programs in oncology, autoimmunity, and inflammatory diseases.
• PBMC/Treg Suppression Assay An immunomonitoring and characterization method that assesses the suppressive function of regulatory T cells through standardized suppression assays on PBMCs and Tregs. Designed for pharmaceutical and biotech researchers evaluating compound efficacy and safety on Treg biology during preclinical development.
• Immunomonitoring and Immunophenotyping Services A comprehensive suite of cellular assays assessing compound efficacy and safety on Treg Biology, including Suppressive Function Assays, Recruitment Analysis, Secretion Profile, Cell Death & Viability Assay, and Tumour Infiltration Analysis. Targeted at pharma and biotech developers needing deep immunophenotyping readouts for lead characterization and safety profiling.
• PDX-Like In Vivo Cancer Models Custom-made preclinical in vivo cancer models using humanized SCID mice (PDX-Like) and syngeneic models, enabling complete monitoring of disease advancement, organ infiltration, and toxicity for compound efficacy and safety assessment. Provided to pharmaceutical and biotechnology clients for oncology drug development programs.

Quantifiable outcome

• Complete transcriptomic study of Tregs and their microenvironment in a single assay
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators2 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Caprion Biosciences: Specialized immunology and proteomics CRO providing biomarker and immune monitoring services to biopharma. Direct comparability through shared focus on immunology-based custom assays for drug discovery and development.
• CellCarta (formerly Caprion Biosciences): Specialty CRO offering immune monitoring, flow cytometry, and biomarker assay services to pharma and biotech. Highly comparable to Immune Insight in serving immuno-oncology and inflammation drug developers with custom assay development and sample analysis.
• Oncodesign: French preclinical CRO with strong oncology and pharmacology capabilities, including in vivo pharmacology and translational services. Comparable as a similarly sized France-headquartered specialty CRO serving biopharma R&D.
• Explicyte: French immuno-oncology contract research organization specializing in preclinical and translational immune monitoring services for cancer therapeutics. Closely comparable as a small, French specialty CRO focused on immunology biomarker and immune-monitoring work for pharma/biotech.

Emerging players

• Inotiv: Preclinical research services provider with in vivo oncology and toxicology capabilities. Comparable as a smaller specialist CRO offering preclinical in vivo work overlapping with Immune Insight's PDX-like cancer model offerings.
• BioAgilytix: Specialty bioanalytical and biomarker CRO with deep immunology expertise in immunogenicity, cell-based assays, and flow cytometry. Comparable as an immunology-focused specialty services peer serving therapeutic developers.

Broad incumbents

• IQVIA: World's largest clinical CRO with growing specialty/immuno-oncology lab services including biomarker strategy and translational work. Incumbent peer serving similar pharma/biotech customers at much larger scale.
• Labcorp Drug Development: Major clinical and preclinical CRO with strong central lab, biomarker, and immunoassay capabilities. Comparable as a broad-scope incumbent offering overlapping immunology and biomarker services to pharma/biotech.
• Charles River Laboratories: Large global CRO with extensive preclinical, discovery, and safety assessment services including immunology and oncology models. Relevant incumbent that can absorb immune-assessment work as part of broader CRO contracts.
• Eurofins Scientific: Global bioanalytical and clinical testing services platform with significant immunology, biomarker, and cell-based assay capabilities. Comparable as a large incumbent offering overlapping immunomonitoring and bioanalytical services at much greater scale.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immune Insight